Myofibroblasts in end-stage heart failure retain the capacity to return to a less activated state, highlighting their potential as targets for antifibrotic therapy.
MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb.
Nagaraju et al. (Wed,) studied this question.